With a strong emphasis on health, aging & well-being, China is a key market of focus for Tsubota. Hence, it is necessary for us to navigate the right pathway in our process of market entry. As a foreign company, we would need extensive knowledge to understand the intricacies involved in the manufacturing and sales of pharmaceuticals and medical devices.

Tsubota is proud to appoint MSQ Ventures as our cross-border transaction advisor. The MSQ team has exhibited their expansive network across various disease fields in China, provided us with timely and accurate feedback, and helped advance the dealmaking process with access to key decision-makers of top biopharmas. Such impressive project management skills combined with effective communication updates have provided us with transparency and reassurance. We are very pleased with the professionalism of the MSQ team and are looking forward to deepening our collaboration and exploring further opportunities in China.

-- Kazuo Tsubota, MD, PhD

President & CEO

We extend our sincere gratitude to the MSQ team for their profound insights into the Chinese biopharmaceutical landscape and for recognizing the significant potential of CFT8919 in the region. MSQ's proven expertise in project management, deal structuring, and local relationships were instrumental in forging our partnership with Betta Pharmaceuticals, marking it as one of the most substantial upfront deals in China for an IND-ready asset. It is with great confidence that we endorse MSQ Ventures as a reliable and expert guide through the intricate landscape of cross-border transactions.

-- Andrew Hirsch

President & CEO

Given GloriaBio's expertise and track record in the development and commercialization of cancer immunotherapies in China, we believe GloriaBio is well suited to further develop motixafortide in Asia. GloriaBio has demonstrated a clear commitment to the motixafortide programs in stem cell mobilization and pancreatic cancer in Asia, and this transaction provides us with additional capital to continue our launch plans in the U.S.

We are very excited about the swift and successful conclusion of this monumental Asian market licensing agreement. The MSQ team showed remarkable agility and a deep understanding of mutual benefits to both parties right from our initial discussions. MSQ's disciplined deal management ensured a seamless process. Echo, with her visionary leadership, expertise, and impressive execution skills, played a key role in making this collaboration happen.

-- Philip Serlin

Chief Executive Officer

We are pleased to enter into this strategic partnership with BioLineRx and are committed to the development and commercialization of motixafortide in Asia, which we believe will bring additional value to GloriaBio's portfolio via clear synergies with zimberelimab. 

The MSQ team's great efforts made a huge impact on the closing of this successful transaction in such a short time. The MSQ team provided valuable advice for both sides. We are impressed with the MSQ team's extensive knowledge of financial structures and drug development.

-- Jiman Zhu

Founder

We would like to express our sincere appreciation for the exceptional work you have done for us. Your team's expertise and vast experience in cross-border partnerships have provided us with invaluable insights. Overall, we highly recommend MSQ Ventures to any company seeking to expand its business globally. Thank you for your exceptional work and support, and we look forward to continuing our partnership with you in the future.

-- Zhong Liu, Ph.D.

Vice President

We were very pleased with MSQ Ventures! They demonstrated industry leading project management skills and diligence for the outreach vetting-selection in approaching potential strategic Chinese investors-partners, which far exceeded our expectations. I would choose MSQ Ventures again for any future investor-partnering processes in China. I highly recommend MSQ without any reservation in the China Healthcare cross-border space.

-- Lou Pascarella

(Former)Chief Executive Officer

ViCardia worked with MSQ Ventures as its exclusive advisor to identify potential strategic partners and financial investors for our entry into the China market.  The MSQ team in New York and Shanghai quickly grasped ViCardia’s innovative and proprietary science-treatment for chronic and acute heart failure.  The MSQ team identified multiple, high-potential strategic partners and investors who have the knowledge, expertise and capital to advance ViCardia’s clinical development program in China and future commercial introduction of ViCardia’s mitotropic agent, GP-531, for treating worsening heart failure.  MSQ Ventures is well-known for its expertise and ViCardia’s experience affirms their depth of knowledge, management skills and broad industry contacts in the life sciences community in China, one of the most important markets for an emerging company like ViCardia.  We highly recommend MSQ Ventures and wish them continued success.

-- Michael Kokesh

CEO & Founder

The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit of combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and chemotherapy in a second-line setting. We believe that this combination could be beneficial to patients in a first-line setting as well, and we hope to confirm this in a randomized trial. We are thrilled to be partners with BioLineRx in the development of this late-stage clinical asset and look forward to initiating this important trial as quickly as possible.

Throughout this journey, MSQ team has demonstrated professionalism and dedication in helping both of our teams to reach the finish line in a timely fashion.

-- Qiang Lu

Chairman and Founder

This collaboration is based on the highly encouraging results from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1 and chemotherapy, which provide strong support for continued development in this very challenging disease. With its broad solid tumor oncology pipeline and highly experienced development team, we believe we have found an outstanding partner in GenFleet to execute a rigorously designed randomized Phase 2b trial.

The MSQ team helped to navigate through the complexity of cross-border transactions and secured this transaction by deploying their deep knowledge of the global market. We are highly impressed with MSQ's “thinking outside the box” approach and their expertise in deal structuring and negotiation.

-- Phil Serlin

Chief Executive Officer

MSQ has a unique competitive advantage with its business intelligence and relationship access to key decision makers within China’s Pharma and Biotech ecosystem. Their proven systematic and methodical approach helped us tremendously in better understanding how our technology and assets differentiate in the evolving competitive landscape, which also led to effective introductions and high-level due diligence with viable partners in China. In the long term, MSQ’s strategic partnering proved quite successful, in helping us develop our partnerships and collaborations in China. We recommend working with MSQ in the cross-border space – both with developing and executing your strategy in China.

-- Ian Wilson
Chief Executive Officer

MSQ is a very trustable and reliable partner in exploring business opportunities in the Great China region. Their consulting services for us outperformed our expectations, which aligns with their existing reputation in Korea.

-- Harry Hunwoo Shin, Ph.D.

Chief Business Officer

MSQ Ventures has been working closely with Xbiome since January 2021 to arrange virtual road show and to explore overseas license-in opportunities around the microbiome area. With its expertise and broad connections in the biotechnology industry, MSQ has greatly facilitated our new BD team to effectively build up relationship with potential business partners. The biweekly work meetings had been well-prepared with clear and concise agenda. Deliverables were always on time and of high quality. We appreciate MSQ’s diligence and professionalism during previous collaboration and hope to work together again in near future.

-- Dr. Yan Tan

Chief Executive Officer

MSQ Ventures, with their expertise and broad connections in China healthcare industry, demonstrates great professionalism and outstanding performance during all the collaborations with us. MSQ team worked closely with us and completed high-quality deliverables on time with acute attention to our needs.

-- Mr. Yuval Gottenstein

Chief Executive Officer

MSQ Ventures used its KOL network to generate and then present valuable insights into the emerging China precision-oncology landscape based on custom-tailored market research. Our weekly project calls were always agenda-driven and highly effective. MSQ’s deep industry relationships allowed us to engage rapidly and effectively with multiple top-tier players. All partnering calls were expertly organized and MSQ clearly had done the pre-work to enable productive discussions. I was extremely impressed overall with the professionalism of the MSQ team across the board.

-- Constantine Chinoporos

Chief Business Officer

Immunecent is impressed by the professional work provided by the MSQ's China and US teams. Together with the MSQ team, we explored numerous collaborative opportunities with many companies from start-ups to MNC giants. MSQ's well-established connection and insightful advice are critical for helping us extend deep conversations with the counterparties quickly. It was amazing to have MSQ, a tier-one cross-border advisory firm, as the go-to person for all our BD activities.

-- Dr. Liguo Zhang

CSO

LEO Pharma rarely out-sources consultancy work due to strong roots and understanding of the medical dermatology landscape. However, for China, we needed some local expertise and reach so we engaged with MSQ Ventures to help us identify and scout innovative assets in the field of medical dermatology from China. It was really nice to work with the team who have local knowledge and expertise to map out the local Biotech Innovation Ecosystem and present some excellent companies and assets for us to help build our pipeline and necessary steps for the future

-- Mr. Rachit Vohra

Director Global Business Development

The MSQ team has been working from A to Z to help us understand China’s market, develop a plan, execute strategic objectives, and advise on this transaction. Their systematic approach and laser focus on results contributed to our success.

-- Mr. Chris Martin

CEO

MSQ team has been working seamlessly as our external team focused on developing and executing China strategy and diligently helped us identify, evaluate and advise on current and future strategic opportunities to continue to expand BioInvent's capability to deliver for cancer patients in the region. We appreciated MSQ's help so that we can complete this transaction smoothly and expediently in mostly virtual fashion during this challenging time.

-- Mr. Martin Welschof

CEO

Working with MSQ enabled us to engage with a broad group of high-quality potential partners across a diverse set of therapeutic areas and focus our efforts on high-fit organizations. In parallel, we were able to quickly gain insight into the unmet needs and commercial potential of our assets in China to better articulate the value of our programs to our potential collaborators.

-- Mr. Carter King

Vice President, Business Development

MSQ is very professional and demonstrated its business intelligence strength in the China Healthcare market by helping us develop our own China market strategy via a superb opportunity assessment project. The deliverables, which included thorough market landscape research and market entry strategy, provided us the focus and momentum with actual partner-investor leads. With our proprietary cell therapy platform, it is very important for Cytovia to have the right positioning when expanding our geographic territory. MSQ assessed market interest and identified well-aligned strategic China-based partners. During this process, MSQ team demonstrated a clear understanding and direct knowledge of the technology and the capital markets, which I believe should lead to future success in China. I am comforted and truly enjoy working with MSQ on our China strategies.

-- Dr. Daniel Teper

Chairman and Chief Executive Officer

We have been working intensively with MSQ Ventures since November 2019 to identify, select and approach potential Chinese investors and corporate partners for our breakthrough technology, aiming for an early partnership for our lead product against severe respiratory infections in the Chinese market.

We are thrilled with the experience with MSQ Ventures. They demonstrated project management skills and diligence for the selection, due diligence, and negotiation with potential investors and partners and far exceeded our expectations. In particular, the support for the two roadshows in China and the United States was the key to the success of our process, but also the intensive and unrelenting follow-up with the identified leads. We would choose MSQ Ventures again for investor processes in China and elsewhere at any time and can recommend MSQ without any reservation. In summary an outstandingly positive experience!

-- Dr. Rainer Lichtengerger

President and Chief Executive Officer

MSQ Ventures presented valuable insights into the China healthcare industry with custom-tailored research development. MSQ’s expertise in the China market and distinguished KOL networks provided us a much clearer picture of the China healthcare industry landscape and gave us valuable insight into the perception of our biologics amongst leading physicians within the China healthcare system. MSQ assisted in enhancing the knowledge of our BD team and thus allowed us to successfully navigate opportunities in China. The MSQ team demonstrated professionalism and dedication in their engagement with KOLs and delivered valuable insight.

-- Mr. Lee Morley

Chief Executive Officer

MSQ provided key insights and informative interviews from KOLs in the research report, helping us to clarify our strategic goals in the Chinese market. MSQ team worked closely with us and completed high-quality deliverables on time with attention to our needs.

-- Dr. Masoud Tavazoie

Chief Executive Officer and Co-founder

MSQ Ventures’ insights into China's healthcare industry were invaluable in enabling my team, and me, to evaluate, accurately, the enormous opportunities, within OBT’s therapeutic space, in China. MSQ’s custom-tailored research and meticulous approach helped my team and I achieve a deeper understanding of the Chinese biotech landscape and effectively establish high-quality partnerships with active biotech investors and biopharma partners within a very short amount of time. 

This was instrumental in me closing a Chinese investment quickly and efficiently. MSQ’s expertise in deal structure, valuation, and negotiation was an important factor in this success. MSQ's extensive network and diligent follow-up of meetings after our first roadshow, the 2019 JP Morgan Conference, and subsequently, our second roadshow, is impressive. 

Throughout the process, the MSQ team demonstrated professionalism and dedication in helping my team accomplish our fundraising and partnering goals. I am confident and excited about the opportunity to execute our objectives in China and to contribute to making China an important and leading player in the immune-oncology space. 

-- Dr. Christian Rohlff

Founder and Chief Executive Officer

We are impressed with MSQ's high-quality deliverables and expertise of China healthcare industry as well as their acute attention to our needs, goals, and timeline. In just two months, MSQ prepared us well for China, as we achieved our goals and gained valuable insights regarding our strategic potential in China. MSQ prepared us for our China trip by helping us attain deep insights into China’s pharmaceutical industry, specifically our vertical. They created an excellent custom-tailored report, which covered top-down market analysis, strategic partners/ investors, competitive landscape, M&A activity, valuation, KOLs, and expert opinions. We had a great roadshow experience during our nine-day trip to China in four major cities, where MSQ Ventures helped arrange high-quality one-on-one meetings with tier 1 Chinese strategics for capital and collaboration opportunities. It was amazing to see how Chinese healthcare has dramatically evolved from a capital, collaborative, communication and sophistication perspective.

-- Mr. Frederic Ors

Chief Executive Officer

The Tier 1 strategic investors MSQ Ventures introduced were of the highest professional quality. The majority of the investors were knowledgeable and well-prepared. They understood our underlying technology and core competencies in short order, which differentiates MSQ Venture’s network in China from other firms.

-- Mr. Boo J. L. Nilsson

Chief Executive Officer

Based on its extensive network in China, MSQ Ventures helped arrange 40+ one-on-one high-quality meetings with tier 1 Chinese strategic and financial investors during our 1-week roadshow in Beijing, Shanghai, and Guangzhou. The entire trip was most efficient as we met the top investors in our industry, and gained an invaluable insight into the China market. The critical materials prepared by MSQ Ventures facilitated our effective communication with the investors as well.

-- Mr. Fareed Kureshy

Founder, Chairman, President and CEO

MSQ Ventures delivered an excellent final report, helping us to understand the Chinese market and vet feasible options. The visualizations were engaging and easy to follow and demonstrated a clear vision of the target product market.  KOL and investor feedback was thorough and informed. We found it insightful to learn in-depth about the healthcare regulatory landscape, including pricing and reimbursement policy trends. MSQ’s quality work is adding value to our forward-looking global plan.

-- Ms. Marguerite Hutchinson

VP, Business Development & Legal Affairs

(In April 2011, Plexxikon became a member of the Daiichi Sankyo Group)

MSQ Ventures’ sink-in cross-border experience is crucial for our China exposure and connections. Early this September, we participated in an investment tour at the Bo’ao Healthcare Summit in Hainan. The area is known as the CFDA free-trade zone and “Green Path” for western pharmaceuticals and medical devices companies to get expediated access to China. Forums and meetings were very well organized and useful. We participated in roundtables and panel discussions with local government officials including Mr. Guobiao Gao, the Deputy Commissioner for Hainan Foods and Drug Administration, and the officers from the National Health Commission. We also get to meet top tier strategic investors at the summit. Healthcare investment leaders were highly interested in our technology scope and addressable market. The communication was at ease with no worries verbally or culturally.

     -- Mr. Richard Paxman

Chief Executive Officer

MSQ Ventures has deep-rooted China network and healthcare experience that validated conference engagement success for Inivata. We were invited to Super Hospital and Evergrande Hospital in Bo’ao Lecheng International Medical Tourism Pilot Zone, the first area in China to import high-end international pharmaceuticals and medical device companies for domestic patients. MSQ arranged one-on-one company presentations for Inivata, promoting healthcare development in the Hawaii of China and helping western companies form a strategic alliance. The Bo’ao Hainan Healthcare Summit and Chengdu Hangzhou Healthcare Conferences were thorough and remarkable which not only presented China’s regulatory landscape, hospital penetration, and market trends but also helped Inivata build up a sophisticated perspective on China strategic opportunities. During the Hangzhou Healthcare Conference, we participated in the World Nobel Laureate Biomedical Innovation Competition, in which we presented Inivata’s technology highlights and received the Best Innovation Award and the Most Valuable Medical Invention Award from government officials and Nobel Laureates including Aaron Ciechanover, Nobel Laureate in Chemistry and Edward I. Moser, Nobel Laureate in Physiology. The communication, feedback and follow-through experience with Chinese strategic investors were effective, which we will leverage to develop far-reaching China strategics.

It is very important to have someone who is familiar with your business and the Chinese culture when you are executing a deal or non-deal roadshow in China. MSQ Ventures excels in this category. They understood our business model, pipeline, and how to communicate our deal opportunity. They were able to strategically match our needs with their top tier Chinese investor network. As a result, we had a successful roadshow in Hangzhou and Shanghai.

-- Dr. Thomas Schlumpberger

Vice President, Corporate Development and Alliance Management

MSQ Ventures, with their expertise and broad connections in China healthcare industry, demonstrates great professionalism and outstanding performance during all the collaborations with us. MSQ Ventures provided a comprehensive and thorough China market assessment report with deep insights into the IVD market landscape and multidisciplinary experts interview including physicians, regulatory and industrial expert, which led to our China roadshow. The 5-day China roadshow trip was well organized with 1-1 meetings with partners and investors, selecting from well-established companies with potential synergies to Singulex’s business strategy. MSQ’s strong global teamwork made my China roadshow experience very smooth, effective, and efficient. A special thanks to the MSQ China team, who navigated all my roadshow meetings. The China team was very helpful in my discussions with potential Chinese partners. I was especially impressed by how quickly the MSQ team understood Singulex’s need which was important to help align with the strategy of the partner and investors. I appreciate the follow-ups in a timely manner, which simplified the roadshow process. I had overall, a very good experience working with MSQ Ventures team.

-- Guido Baechler

President and Chief Executive Officer, Singulex